The role that guanylate binding protein 1 (GBP1) plays in cervical cancer is still controversial. The effects of GBP1 on cervical cancer were investigated by Chinese researchers from the Xinjiang Medical University.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.
Corbus Pharmaceuticals Holdings Inc. has obtained FDA clearance of its IND application for CRB-601, a TGF-β-blocking monoclonal antibody targeting the integrin αvβ8. Enrollment in a first-in-human phase I study will open in the first half of this year.
Colorectal cancer (CRC) is a heterogeneous malignancy that starts with the sequential transformation of normal mucosa to adenoma and finally to carcinoma, when it attains metastatic potential. The most frequent metastatic site in CRC is the liver. Researchers from Nanjing Medical University and collaborators identified a significant overexpression of procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3) in liver metastasis tissue samples.
Keiferx LLC has expanded its exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities for the treatment of multiple disease indications.
RSS
